Eric Lawitz

42.9k total citations · 14 hit papers
317 papers, 16.3k citations indexed

About

Eric Lawitz is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eric Lawitz has authored 317 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Hepatology, 220 papers in Epidemiology and 66 papers in Infectious Diseases. Recurrent topics in Eric Lawitz's work include Hepatitis C virus research (197 papers), Liver Disease Diagnosis and Treatment (173 papers) and Hepatitis B Virus Studies (97 papers). Eric Lawitz is often cited by papers focused on Hepatitis C virus research (197 papers), Liver Disease Diagnosis and Treatment (173 papers) and Hepatitis B Virus Studies (97 papers). Eric Lawitz collaborates with scholars based in United States, France and Germany. Eric Lawitz's co-authors include John G. McHutchison, Fred Poordad, Stefan Zeuzem, M. Rodríguez‐Torres, Stuart C. Gordon, Bruce R. Bacon, Clifford A. Brass, Janice K. Albrecht, Rohit Loomba and Zachary Goodman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Eric Lawitz

296 papers receiving 15.9k citations

Hit Papers

Treatment of HCV Infection by Targeting MicroRNA 2009 2026 2014 2020 2013 2011 2009 2010 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of HCV Infection by Targeting MicroRNA
    2013 1.7k citations Eric Lawitz, Stefan Zeuzem et al. profile →
  2. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    2011 1.2k citations Eric Lawitz, Stefan Zeuzem et al. profile →
  3. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Eric Lawitz et al. profile →
  4. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    2010 515 citations Eric Lawitz et al. profile →
  5. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
    2012 454 citations Eric Lawitz et al. profile →
  6. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    2013 438 citations Eric Lawitz, Fred Poordad et al. profile →
  7. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
    2017 435 citations Rohit Loomba, Eric Lawitz et al. profile →
  8. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
    2018 424 citations Arun J. Sanyal, Brent A. Neuschwander‐Tetri et al. profile →
  9. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
    2024 353 citations Rohit Loomba, Mark L. Hartman et al. profile →
  10. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    2023 282 citations Rohit Loomba, Manal F. Abdelmalek et al. profile →
  11. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
    2017 271 citations Edward Gane, Eric Lawitz et al. profile →
  12. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
    2018 257 citations Rohit Loomba, Zeid Kayali et al. profile →
  13. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
    2024 217 citations Eric Lawitz, Elisabetta Bugianesi et al. profile →
  14. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
    2024 44 citations Rohit Loomba, Eric Lawitz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Lawitz United States 63 11.6k 11.0k 2.7k 2.6k 1.7k 317 16.3k
Hiromitsu Kumada Japan 70 13.8k 1.2× 16.1k 1.5× 2.0k 0.7× 1.8k 0.7× 706 0.4× 554 19.9k
Yasuji Arase Japan 52 8.7k 0.8× 9.1k 0.8× 878 0.3× 873 0.3× 1.1k 0.6× 394 11.6k
Wan‐Long Chuang Taiwan 53 8.3k 0.7× 8.5k 0.8× 939 0.3× 733 0.3× 563 0.3× 513 11.1k
Tarik Asselah France 58 9.3k 0.8× 9.3k 0.8× 1.1k 0.4× 1.3k 0.5× 428 0.2× 290 12.0k
Eiji Tanaka Japan 53 7.7k 0.7× 7.9k 0.7× 1.1k 0.4× 595 0.2× 412 0.2× 280 11.2k
Namiki Izumi Japan 58 8.3k 0.7× 11.1k 1.0× 1.1k 0.4× 599 0.2× 264 0.2× 366 13.8k
Markus Peck‐Radosavljevic Austria 66 8.4k 0.7× 9.7k 0.9× 1.9k 0.7× 477 0.2× 566 0.3× 376 14.7k
Keyur Patel United States 47 5.2k 0.5× 5.3k 0.5× 1.8k 0.7× 416 0.2× 438 0.3× 175 8.5k
Pietro Lampertico Italy 54 12.0k 1.0× 11.1k 1.0× 994 0.4× 1.2k 0.5× 268 0.2× 418 14.5k
Osamu Yokosuka Japan 63 10.5k 0.9× 11.6k 1.1× 3.3k 1.2× 1.3k 0.5× 187 0.1× 668 19.0k

Countries citing papers authored by Eric Lawitz

Since Specialization
Citations

This map shows the geographic impact of Eric Lawitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Lawitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Lawitz more than expected).

Fields of papers citing papers by Eric Lawitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Lawitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Lawitz. The network helps show where Eric Lawitz may publish in the future.

Co-authorship network of co-authors of Eric Lawitz

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Lawitz. A scholar is included among the top collaborators of Eric Lawitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Lawitz. Eric Lawitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frías, Juan P., Robert Schmouder, Eric Lawitz, et al.. (2025). Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis. Alimentary Pharmacology & Therapeutics. 63(5). 637–647. 1 indexed citations
2.
Hartman, Mark L., Rohit Loomba, Eric Lawitz, et al.. (2025). Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide. JHEP Reports. 7(8). 101472–101472. 1 indexed citations
3.
Getz, Elise Burmeister, Richard R. Stein, Martin Fink, et al.. (2025). Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function. Clinical Pharmacology & Therapeutics. 117(5). 1358–1368.
4.
Younossi, Zobair M., Homie Razavi, Michael S. Sherman, et al.. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 61(9). 1467–1478. 8 indexed citations
5.
6.
Alkhouri, Naim, Jeffrey E. Edwards, Fred Poordad, et al.. (2024). Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver International. 44(4). 966–978. 10 indexed citations
7.
8.
Lawitz, Eric, Thomas Reiberger, Jörn M. Schattenberg, et al.. (2023). Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study. Hepatology Communications. 7(11). 8 indexed citations
9.
Ratziu, Vlad, Marcus Hompesch, Janani Iyer, et al.. (2023). Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. Journal of Hepatology. 80(2). 335–351. 47 indexed citations
10.
Ratziu, Vlad, Stephen A. Harrison, V. Loustaud‐Ratti, et al.. (2022). Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. Journal of Hepatology. 78(3). 479–492. 73 indexed citations
11.
Ratziu, Vlad, Mary E. Rinella, Brent A. Neuschwander‐Tetri, et al.. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology. 76(3). 506–517. 87 indexed citations
12.
Younossi, Zobair M., Vincent Wai‐Sun Wong, Quentin M. Anstee, et al.. (2020). Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes. Hepatology Communications. 4(11). 1637–1650. 42 indexed citations
13.
Lawitz, Eric, Fred Poordad, Julio Gutiérrez, et al.. (2020). Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study. Health Science Reports. 3(2). e145–e145. 5 indexed citations
14.
15.
Younossi, Zobair M., Maria Stepanova, Eric Lawitz, et al.. (2018). Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib. Liver International. 38(10). 1849–1859. 74 indexed citations
16.
Lawitz, Eric & Fernando E. Membreno. (2014). Response‐guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects. Journal of Gastroenterology and Hepatology. 29(8). 1574–1581. 12 indexed citations
17.
Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454. 5 indexed citations
18.
Lawitz, Eric, John M. Hill, Bradley Vince, et al.. (2013). 847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS. Journal of Hepatology. 58. S347–S347. 5 indexed citations
19.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2011). FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA. UCL Discovery (University College London). 12 indexed citations
20.
Lawitz, Eric, R. Gary Rozier, Thomas Marbury, et al.. (2009). 622 SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS. Journal of Hepatology. 50. S229–S229. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiromitsu Kumada Breakdown of academic impact, for papers by Yasuji Arase Breakdown of academic impact, for papers by Wan‐Long Chuang Breakdown of academic impact, for papers by Tarik Asselah Breakdown of academic impact, for papers by Eiji Tanaka Breakdown of academic impact, for papers by Namiki Izumi Breakdown of academic impact, for papers by Markus Peck‐Radosavljevic Breakdown of academic impact, for papers by Keyur Patel Breakdown of academic impact, for papers by Pietro Lampertico Breakdown of academic impact, for papers by Osamu Yokosuka
Rankless by CCL
2026